| Local project reference | Project Short title | Project Full title | Recruitment end date |
| 1002346 | IMPACT | Identification of Men with a genetic predisposition to ProstAte Cancer: Targeted Screening in men at higher genetic risk and controls – The IMPACT study. | 31/12/2018 |
| 1002349 | UK TTP Registry | United Kingdom Thrombotic Thrombocytopenic Purpura Registry: A prospective study of Thrombotic Thrombocytopenic Purpura in the UK | 31/12/2018 |
| 1006384 | UKAITPR | United Kingdom Adult Idiopathic Thrombocytopenic Purpura (ITP) Registry: An Investigation of Disease Progression, Treatment Effectiveness, and Co-morbid Conditions | 12/06/2020 |
| 1113483 | UKALL 14 | A randomized trial for adults with newly diagnosed acute lymphoblastic leukaemia | 28/12/2018 |
| 1205649 | ICON8 Trial Programme | ICON8 and ICON8B – ICON8 Trial Programme (as per protocol v5 dated 17/12/2014) | 01/07/2019 |
| 1207668 | LI-1 | Leukaemia Lymphoma Research and NCRI Working Group Pick a Winner Programme (LI1) Trial | 13/07/2019 |
| 1207674 | SEARCH | A population based study of genetic predispositions and gene-environment interactions in cancer | 30/09/2019 |
| 1210711 | ESPAC-4 | EUROPEAN STUDY GROUP FOR PANCREATIC CANCER – TRIAL 4. Combination versus single agent chemotherapy in resectable pancreatic ductal and peri-ampullary cancers. | 31/12/2018 |
| 1210712 | INTERLACE | A phase III multicentre trial of weekly induction chemotherapy followed by standard chemoradiation versus standard chemoradiation alone in patients with locally advanced cervical cancer | 01/12/2019 |
| 1301726 | UKALL 2011 | United Kingdom National Randomised Trial for Children and Young Adults with Acute Lymphoblastic Leukaemia and Lymphoma 2011 | 30/04/2019 |
| 1303754 | OPTIMA | Optimal Personalised Treatment of early breast cancer using Multiparameter Analysis | 31/01/2020 |
| 1303754b | Optima (Main Trial) | Optimal Personalised Treatment of early breast cancer using Multi-parameter Analysis | 31/01/2020 |
| 1305779 | IoN | IoN Is ablative radio-iodine necessary for low risk differentiated thyroid cancer patients | 01/02/2019 |
| 1311856 | RAPPER | Radiogenomics: assessment of polymorphisms for predicting the effects of radiotherapy | 31/03/2022 |
| 1408971 | AML18 | A Trial for Older Patients with Acute Myeloid Leukaemia and High Risk Myelodysplastic Syndrome | 20/10/2020 |
| 1411013 | FOCUS 4 | FOCUS4 – Molecular selection of therapy in colorectal cancer: a molecularly stratified randomised controlled trials programme | 01/01/2019 |
| 1412029 | IHCAP | Investigating Hereditary Cancer Predisposition – a combined genomics approach | 31/05/2020 |
| 1502056 | The Molecular Investigation of Unexplained Anaemias | The Molecular Investigation of Unexplained Anaemias and Related Congenital Anaemias | 30/11/2023 |
| 1503071 | FLAIR | FLAIR: Front-Line therapy in CLL: Assessment of Ibrutinib + Rituximab | 30/01/2020 |
| 1508136 | MCL Biobank Observational Study | Establishing a Biobank and Database as a National Resource for Characterising Indolent and Aggressive forms of Mantle Cell Lymphoma, an Observational Study. | 30/10/2019 |
| 1601198 | Add-Aspirin Trial | A phase III, double blind, placebo controlled, randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumours | 01/08/2021 |
| 1603225 | ACELARATE | A phase III, open label, multicentre randomised clinical study comparing Acelarin (NUC-1031) with Gemcitabine in patients with metastatic pancreatic carcinoma (ACELARATE: Acelarin first line randomised pancreatic study) | 31/12/2020 |
| 1604237 | SelPac | SELPAC Uveal Melanoma Study | 31/12/2018 |
| 1608296 | APE | Hartmann’s type procedure versus intersphincteric APE in patients undergoing resection of rectal cancer in whom restoration of gastrointestinal continuity is not appropriate: a multi centre, prospective observational study | 30/06/2019 |
| 1610318 | AML19 | Adults with acute myeloid leukaemia or high-risk myelodysplastic syndrome | 09/11/2021 |
| 1612350 | INCA | A multicentre randomised phase II clinical trial of Inotuzumab Ozogamicin plus Rituximab and CVP (IORCVP) versus Gemcitabine plus Rituximab and CVP (GemRCVP) for the first line treatment of patients with diffuse large B cell lymphoma who are not suitable for anthracycline containing chemotherapy | 31/10/2018 |
| 1701365 | The UK National Registry of Chronic Myeloid Leukaemia | The UK National Registry of Chronic Myeloid Leukaemia | 14/07/2020 |
| 1702374 | Prepare-ABC | Supportive Exercise Programmes for Accelerating Recovery after major Abdominal Cancer surgery (PREPARE-ABC) | 01/05/2020 |
| 1703389 | C31004 | A Phase 2, Randomized Study of MLN0128 (a Dual TORC1/2 Inhibitor), MLN0128+MLN1117 (a PI3Kα Inhibitor), Weekly Paclitaxel, or the Combination of Weekly Paclitaxel and MLN0128 in Women With Advanced, Recurrent, or Persistent Endometrial Cancer | 30/09/2018 |
| 1703390 | CONCEPT | CONCEPT: A Phase II pilot study of 3 weekly Cabazitaxel versus weekly Paclitaxel chemotherapy in the first line treatment of Her2 negative metastatic breast cancer (mBC) | 31/12/2020 |
| 1703394 | IMRiS | IMRiS: Phase II study of IMRT in primary bone and soft tissue sarcoma | 04/10/2018 |
| 1703398 | CANC – 4658 | A non-interventional biomarker study in patients with Non-Small Cell Lung Cancers (NSCLCs) of adenocarcinoma tumour histology treated in second line with nintedanib in combination with docetaxel | 01/02/2019 |
| 1704403 | TREATT | A double blind, randomised controlled trial evaluating the safety and efficacy of Tranexamic acid in patients with haematological malignancies with severe thrombocytopenia | 31/08/2019 |
| 1705427 | Head & Neck 5000 Follow Up Study | Head & Neck 5000 Follow Up Study | 31/03/2019 |
| 1708470 | plasmaMATCH | plasmaMATCH – A multiple parallel cohort, non-randomised, open label, multi-centre phase IIa clinical trial aiming to provide proof of principle efficacy for designated targeted therapies in patients with advanced breast cancer where the targetable mutation is identified through ctDNA screening | 31/05/2019 |
| 1708476 | TAMARIN | Effects of TAMoxifen on the Mutant Allele Burden and Disease Course in Patients with MyeloprolifeRatIve Neoplasms | 31/12/2018 |
| 1708490 | PRIMETIME | Post-operative avoidance of radiotherapy in minimal risk women: patient selection using biomarkers | 24/01/2021 |
| 1710507 | Niraparib in men with mCRPC and DNA repair anomalies | A Phase 2 Efficacy and Safety Study of Niraparib in men with Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies | 29/06/2019 |
| 1712540 | CHRONOS-4 | A Phase III, randomized, double-blind, controlled, multicenter study of intravenous PI3K inhibitor copanlisib in combination with standard immunochemotherapy versus standard immunochemotherapy in patients with relapsed indolent non-Hodgkin’s lymphoma (iNHL) – CHRONOS-4 |
31/12/2019 |
| 1712541 | Astellas AML Maintenance Study | A Phase 3 Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial of the FLT3 Inhibitor Gilteritinab (ASP2215) Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects with FLT3/ITD AML in First Complete Remission | 14/03/2019 |
| 1802571 | CR UK Stratified Medicine Pilot study | The Cancer Research UK Stratified Medicine Programme: Pilot Study | 31/12/2020 |
| 1802579 | PRAN-16-52 | PHASE III, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, RANDOMIZED STUDY OF PRACINOSTAT IN COMBINATION WITH AZACITIDINE IN PATIENTS ≥18 YEARS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA UNFIT FOR STANDARD INDUCTION CHEMOTHERAPY | 30/12/2019 |
| 1804571 | Open Label Study of Relugolix in Men with Advanced Prostate Cancer | HERO: A Multinational Phase 3 Randomized, Open-label, Parallel Group Study to Evaluate the Safety and Efficacy of Relugolix in Men with Advanced Prostate Cancer | 01/10/2018 |
| 1805626 | LCH-IV | LCH-IV International Collaborative Treatment Protocol for Children and Adolescents with Langerhans Cell Histiocytosis |
01/12/2020 |
| 1805629 | MERU | A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Subjects with Extensive Stage Small Cell Lung Cancer (MERU) | 31/01/2019 |
| 1805632 | National Lung Matrix | National Lung Matrix Trial: Multi-drug, genetic marker-directed, non-comparative, multi-centre, multi-arm phase II trial in non-small cell lung cancer | 01/10/2021 |
| 1810695 | OPINION | OPINION – A Phase IIIb, Single-arm, Open-label Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed non- Germline BRCA Mutated Ovarian Cancer Patients who are in Complete or Partial Response Following Platinum based Chemotherapy | 30/03/2019 |
| 1810700 | PLATO | PLATO – PersonaLising Anal cancer radioTherapy dOse – Incorporating Anal Cancer Trials (ACT) ACT3, ACT4 and ACT5 |
31/01/2022 |
| 1812731 | B-AHEAD3 | A randomised phase II trial of intermittent energy restriction and resistance exercise in women receiving chemotherapy for advanced breast cancer. | 28/02/2020 |
| 1901749 | CALLS | A Cohort Study To Establish the Prevalence of Mutations in Patients with CML Who Meet the ELN Criteria for Warning or Failure and Patients With Ph+ALL With Detectable BCR-ABL1 Currently Being Treated With First or Subsequent TKI Therapy in the UK Using Next Generation Sequencing | 31/12/2018 |
| 1902765 | Ribociclib Non-Interventional Study | Prospective observational study to describe effectiveness and socio-economic impact of ribociclib in clinical practice in the United Kingdom | 29/06/2019 |
| 2003/7/145 | NSCCG | NSCCG – National Study of Colorectal Cancer Genetics | 30/09/2018 |
| 604071 | STAMPEDE | Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy | 31/12/2020 |
| 701001 | UK Genetic Prostate Cancer Study | UK Genetic Prostate Cancer Study | 01/10/2019 |
Updated 17/09/2018